Albany International Corp.AINNYSE

52-Week Range41-74

41.15Current 51.2174.16

Want to monitor AIN?

Get notified when price crosses targets, volume spikes, or RSI hits oversold

Gross Margin

Operating Margin

Revenue Growth

albany international is a global advanced textiles and materials processing company with two core businesses.

A. William Higgins

Explore More

Filter and sort all 500 stocks

Today's biggest gainers and losers

Visual sector performance

Alerts

News

Apollo Global Management, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - APO

The Iran war is sending shockwaves through the world's busiest IPO market

Novartis to Buy Breast-Cancer Drug From Synnovation for Up to $3 Billion

Transaction in Own Shares

The 15-20 National Hospital and GenSight Biologics Announce the First Treatments in the French Named Patient Early Access Program (AAC) for GS010/LUMEVOQ®

China's record oil output reaches limits of what's possible

Novartis to buy breast cancer drug candidate from Synnovation

Milestone Pharmaceuticals Gears Up For Q4 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts

Flex LNG - Notice of Annual General Meeting 2026

What if ASML Becomes the Next Trillion-Dollar Stock?

Alibaba workforce shrinks 34% in 2025 as Chinese tech giant doubles down on AI

Geely: Positive On Profit Surge And Favorable Prospects

KD Investors Have Opportunity to Lead Kyndryl Holdings, Inc. Securities Fraud Lawsuit with the Schall Law Firm

Paysafe Limited Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - PSFE

BellRing Brands, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - BRBR

Novartis to Acquire Synnovation Therapeutics' Pan-Mutant Selective PI3Kα Inhibitor Program

Should You Buy Lockheed Martin Stock Right Now?

Tripadvisor: Activist Pressure Supports Our Upside Outlook

Standard Chartered, BSI lose bid to join cases in Singapore winding up firms with assets linked to 1MDB

Novartis agrees to acquire a pan-mutant-selective PI3Kα inhibitor, strengthening its breast cancer pipeline

About